Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Schmoll on the Objective of CHARTA for CRC

Hans-Joachim Schmoll, MD
Published: Wednesday, Aug 09, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

The CHARTA trial investigates the potential activity of FOLFOX plus bevacizumab (Avastin) with or without irinotecan, explains Schmoll. The primary endpoint of the study was the improvement of progression-free survival at 9 months.
 


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

The CHARTA trial investigates the potential activity of FOLFOX plus bevacizumab (Avastin) with or without irinotecan, explains Schmoll. The primary endpoint of the study was the improvement of progression-free survival at 9 months.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x